Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT07152782CT.gov T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis | — | Not Yet Recruiting | — | — | — |
NCT06374459CT.gov Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | — | Recruiting | — | — | — |
NCT06255392CT.gov Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06268652CT.gov Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | — | Recruiting | — | — | — |
NCT05840211CT.gov Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | — | Active Not Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03925233CT.gov Breast Cancer Treatment Based on Organ-like Culture | — | Unknown | — | — | — |
Show 16 more trialsShow fewer
NCT03691051CT.gov A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03101748CT.gov Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT03080805CT.gov Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) | — | Unknown | — | — | — |
NCT02973737CT.gov A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT02672475CT.gov Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02422199CT.gov A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab | — | Unknown | — | — | — |
NCT01349088CT.gov Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01158274CT.gov RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT00684983CT.gov Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | — | Completed | — | — | — |
NCT00479856CT.gov Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | — | Terminated | — | — | — |
NCT00077363CT.gov Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00068588CT.gov GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | University Health Network, Toronto | P3 | BB · 66 |
| Trastuzumab | SWOG Cancer Research Network | P4 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P3 | BBB |
| Zoledronate | Washington University School of Medicine | P4 | BBB |
| Tamoxifen | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Trastuzumab Deruxtecan | SWOG Cancer Research Network | P4 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BBB |
| Dexasone | Tianjin Medical University Cancer Institute and Hospital | P4 | BBB |
| Olaparib | The Netherlands Cancer Institute | P4 | BBB |
+42 more in the Breast Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →